HPV – Page 51 – Oral Cancer News

Learn the risk factors of oral cancer

Source: King5TV Author: Elizabeth Berman Tens of thousands of people will be diagnosed with oral cancer this year. Only half will survive five years. 75% of dentists do not screen for oral cancer which is why it goes undetected and spreads throughout the body before it’s too late. There is now a link between oral cancer being transmitted by oral sex even. Local dentist (of Woodinville, WA), Dr. Michael Koczarski offers life saving screening known as VELscope which uses a bright blue light to illuminate the mouth. The screening can reveal tiny lesions that could be signs of oral cancer. It’s a quick, painless and non-invasive test that can illuminate abnormalities in the mouth before they are visible to the naked eye. • Oral cancer is a disfiguring and life-threatening cancer that affects 34,000 Americans each year and kills roughly one person every hour. • The death rate percentage for those with oral cancer is greater than that of breast cancer. • A disturbing new find is that it’s not all due to tobacco or alcohol use. It has been reported that the increase in oral cancer among younger people is due to a link between oral sex and HPV – the same virus linked to cervical cancer. • Dr. Michael Koczarski is one of the first dentists to adopt VELscope early detection technology for oral cancer screening. In honor of Oral Cancer Awareness Month in April, Dr. Koczarski is offering a free VELscope screening with every exam performed in April. Patients can schedule their [...]

Charlotte Parker2010-04-04T08:41:51-07:00April, 2010|Oral Cancer News|

Another call to extend HPV vaccine to boys. Is anyone listening?

Source: www.abc.net.au Author: Lindy Kerin Australian researchers say the human papillomavirus (HPV), which can cause cervical cancer in women, is now a leading cause of oral cancer in men in the Western world. The news has reignited debate over whether the HPV vaccine, which is free for young women, should also be offered to men. A University of Sydney study shows that 60 per cent of throat and tonsil cancers are caused by the virus. "We've tested just over 300 cancers of the oropharynx, and the oropharynx includes the tonsil and the base of tongue and part of the pharangyl wall," said Barbara Rose, an Associate Professor in research at the University of Sydney. "We've tested those for the human papillomavirus type-16 and type-18, which are the major cause of cervical cancer in women. "And we found a sizeable proportion are associated with those types. In fact, probably in excess of 50 per cent now." Those figures from 2001 to 2005 increased to almost 60 per cent in 2006 and 2007. Associate Professor Rose says head and neck cancers have traditionally been associated with older men and related to alcohol and smoking. She says these findings show that has now changed and most are due to the increasing practise of oral sex. "We now know that there's another subset, which is quite distinct biologically, which tends to affect younger people who don't smoke and don't drink, caused by human papillomavirus probably by sexual transmission," she said. "And the types of [...]

Oral Cancer Foundation News Team - A2010-04-19T22:26:55-07:00April, 2010|Oral Cancer News|

Research argues HPV vaccine should extend to boys

Source: RadioAustralia.net Author: Staff It is already available free to young girls in countries like Nauru, Vanuatu, Tuvalu and Cook Islands, but researchers are now saying the human papilloma virus, or HPV, vaccine Gardasil should also be offered to males. It follows new Australian research showing that the virus which causes cervical cancer in women is now a leading cause of oral cancer in men. It says 60 per cent of throat and tonsil cancers are caused by the virus. Presenter: Lindy Kerin Speaker: Barbara Rowe, associate professor in research with University of Sydney; Luke Connolly, director of Australian Centre for Economic Research; Dr Jonathan Clark, head and neck surgeon with Royal Prince Alfred and Liverpool Hospitals, New South Wales LINDY KERIN: For the past two years Australia has been rolling out the cervical cancer vaccine Gardasil to young women. It immunises them against the human papilloma virus, or HPV as it's known. Now there's growing evidence that the same virus is responsible for an increasing number of mouth and throat cancers in men. Barbara Rowe is an associate professor in research at the University of Sydney. BARBARA ROWE: We've tested just over 300 cancers of the oropharynx, and the oropharynx includes the tonsil and the base of tongue and part of the pharangyl wall. And we've tested those for the human papilloma virus type-16 and type-18, which the major cause of cervical cancer in women. And we found a sizeable proportion are associated with those types. In fact probably [...]

Charlotte Parker2010-04-01T17:14:59-07:00April, 2010|Oral Cancer News|

Oral sex and HPV related cancers – a threat for both sexes

Source: Examiner.com Author: Charles Simmins An editorial in the British Medical Journal on March 25 links the increasing incidence of oropharyngeal squamous cell carcinoma to infections by human papillomavirus (HPV) that patients caught through oral sex. HPV infection is known to be related to cancers of the cervix, as well as vulvar, vaginal, and male anal cancers. The United States has seen a 22% increase in this oral cancer from 1999 to 2006 and the United Kingdom a 51% increase from 1989 to 2006. The editorial reports that biopsies of these cancers in the United States are showing a 50% to 100% increase in HPV findings over a decade. The authors point to recent studies that show the risks of developing oropharyngeal carcinoma are increased in those patients with six or more lifetime sexual partners, four or more lifetime oral sex partners and, for men, an earlier age at first sexual intercourse. The implications of these findings suggest reconsideration of some basic healthcare issues. In an e-mail exchange with William Bonnez, M.D., Associate Professor of Medicine at the University of Rochester, he pointed out that no screening tools exist for HPV related cancers other than the Pap smear for cervical cancer. The authors of the editorial report that HPV oropharyngeal squamous cell carcinoma appears to have a more favorable prognosis than the non-HPV variety, and that those affected are usually younger. They point out that this means the patients will be dealing with the illness and its effects for a longer period [...]

Charlotte Parker2010-04-01T19:39:12-07:00April, 2010|Oral Cancer News|

Sharp rise in HPV-related oropharyngeal carcinoma — a legacy of the “sexual revolution”?

Source: MedScape Today Author: Zosia Chustecka March 30, 2010 — The incidence of oropharyngeal carcinoma related to human papillomavirus (HPV) has been increasing in recent years, and there is speculation that this is the result of the "sexual revolution" of the 1960s. This increase in the incidence of HPV-related oropharyngeal cancer has important public health implications, British experts warn in an editorial published online March 25 in the British Medical Journal. HPV-related oropharyngeal carcinoma appears to be a new and distinct disease entity, with better survival than the classic non-HPV-related disease, they point out. "These patients are typically younger and employed, and — because outcomes seem to be more favorable than for patients with non-HPV-related carcinoma — they will live longer with the functional and psychological sequelae of their treatment. Consequently, they need prolonged support from health, social, and other services, and may require help returning to work," write the authors, headed by Hisham Mehanna, BMedSc, MB ChB, FRCS, director of the Institute of Head and Neck Studies and Education at University Hospital in Coventry, United Kingdom. However, currently, there is no good evidence to support managing patients with HPV-related head and neck cancer differently from those whose tumors are not HPV-related, the researchers write. Several studies are being planned to evaluate different treatment options, and Dr. Mehanna and colleagues urge clinicians to offer all patients with oropharyngeal cancer the opportunity to enroll in a clinical trial. However, until data from those trials are available, "we suggest that clinicians should not change their [...]

Charlotte Parker2010-04-01T19:38:46-07:00April, 2010|Oral Cancer News|

Rise in mouth cancer linked to STI’s, primarily HPV16

Source: www.nhs.uk Author: staff The Daily Telegraph reported that a “rise in mouth cancer may be due to sexually transmitted infection”. The newspaper said that there has been a 50% increase in the number of mouth cancers in the last 20 years, and the increase appears to be in those cases related to the human papilloma virus (HPV). The story is based on an editorial in the British Medical Journal by cancer specialists, which highlighted an increase in the numbers of a specific type of throat cancer in the UK. The specialists also discussed studies from other countries that show an increase in the proportion of HPV-related throat cancers. The editorial reported on a very small number of studies, but it shows that there may be a need to investigate the incidence of HPV-related throat cancers in the UK, to track these cases and to see if HPV-related cancers should be treated differently to non-HPV-related throat cancers. There is insufficient evidence at the moment to suggest that the HPV vaccination, currently available for teenage girls, should also be given to boys. Where did the story come from? This editorial was written by Hisham Mehanna, director of the Institute of Head and Neck Studies and Education at University Hospital, Coventry, and colleagues at the University of Liverpool, Université Catholique de Louvain and the University of Texas. The editorial was commissioned and published by the British Medical Journal and was not externally peer reviewed. What was the editorial about? This editorial was [...]

Oral Cancer Foundation News Team - A2010-04-19T22:27:55-07:00March, 2010|Oral Cancer News|

Study evaluating clinical performance of Cervista(R) HPV HR presented at AOGIN

Source: www.prnewswire.com Author: press release Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that interim data from the first large-scale independent evaluation of clinical performance of Cervista® HPV HR compared to Hybrid Capture 2 (hc2), were presented at the 4th Biennial Meeting of AOGIN (Asia-Oceanic Research Organization in Genital Infection and Neoplasia) in New Delhi, India on March 26-28, 2010. Cervista HPV HR is a diagnostic test for the detection of 14 high-risk human papillomavirus (HPV) types. The study, SHENCCAST II, is a major cervical cancer screening trial including more than 10,000 women that is being conducted in China to evaluate the performance of HPV assays, among other endpoints. A preliminary analysis of data from 5,043 patients showed the Cervista HPV HR test performed as follows: Overall HPV positivity for this cohort was 12.2 percent for the Cervista HPV HR test and 14.6 percent with the hc2 test. For histologically confirmed CIN 2 or more severe lesions, the Cervista HPV HR test showed a sensitivity of 90.7 percent and a specificity of 90.2 percent. For the hc2 test, sensitivity and specificity were 94.7 percent and 87.9 percent, respectively. While the Cervista HPV HR test demonstrated improved specificity and the hc2 test yielded higher sensitivity, a statistical analysis of overall test accuracy that plots sensitivity and specificity found the two methods were clinically equivalent (area under the ROC [...]

Oral Cancer Foundation News Team - A2010-03-29T20:21:43-07:00March, 2010|Oral Cancer News|

Oropharyngeal carcinoma related to human papillomavirus

Source: BMJ 2010;340:c1439 Author: Staff Incidence is increasing rapidly, with implications for prognosis and policy Head and neck cancer is the sixth most common cancer, with about 640,000 new cases each year worldwide. Despite an overall marginal decline in the incidence of most head and neck cancers in recent years,1 the incidence of oropharyngeal squamous cell carcinoma has increased greatly, especially in the developed world. In the United States, the incidence of oropharyngeal squamous cell carcinoma increased by 22% from 1.53 per 100,000 to 1.87 per 100,000 between 1999 and 2006, after showing no change between 1975 and 1999. 1 The United Kingdom has seen a 51% increase in oral and oropharyngeal squamous cell carcinoma in men from seven per 100,000 to 11 per 100,000 between 1989 and 2006. 2 The increase in incidence of oropharyngeal squamous cell carcinoma seems to be accounted for by a rise in human papillomavirus (HPV) related oropharyngeal carcinoma. A recent retrospective study showed a progressive proportional increase in the detection of HPV in biopsies taken to diagnose oropharyngeal squamous cell carcinoma in the Swedish county of Stockholm over the past three decades (23.3% in 1970s, 29% in 1980s, 57% in 1990s, 68% between 2000 and 2002, 77% between 2003 and 2005, and 93% between 2006 and 2007).3 Similarly, HPV related oropharyngeal carcinoma has been reported in 60-80% of recent oropharyngeal biopsy samples in studies conducted in the US, compared with 40% in the previous decade.4 More research is needed to establish the incidence of HPV related oropharyngeal carcinoma in African, Asian, and South American countries. HPV related oropharyngeal carcinoma seems to be a new and distinct [...]

Charlotte Parker2010-03-26T16:16:09-07:00March, 2010|Oral Cancer News|

HPV-related cancer leap to have big impact on health services

Source: www.dentistry.co.uk Author: staff The rapid rise in cases of squamous cell carcinoma related to human papillomavirus (HPV) infection has serious implications for health services around the world, warn researchers. They suggest that sexual transmission of HPV might be the reason for the rise. Head and neck cancer is the sixth most common cancer, with about 640,000 new cases each year worldwide. Despite an overall marginal decline in most head and neck cancers in recent years, the level of oropharyngeal squamous cell carcinoma (OSCC) has increased greatly, especially in the developed world. In the US, cases increased by 22% between 1999 and 2006, after showing no change between 1975 and 1999, while the UK has seen a 51% increase in oral and oropharyngeal cancer in men between 1989 and 2006. This increase seems to be accounted for by a rise in HPV-related tumours, say the authors, led by Hisham Mehanna at the Institute of Head and Neck Studies and Education, University Hospital, Coventry. A recent study showed a 70% increase in the detection of HPV in biopsies taken to diagnose oropharyngeal carcinoma in Stockholm since the 1970s. HPV-related oropharyngeal carcinoma has also been reported in 60-80% of recent biopsy samples in studies conducted in the US, compared with 40% in the previous decade. HPV-related oropharyngeal carcinoma seems to be a new and distinct disease entity, explain the authors. It has a better prognosis than non-HPV related oropharyngeal carcinoma, particularly in non-smokers, but the reason for this improved survival is not [...]

Oral Cancer Foundation News Team - A2010-03-24T14:33:53-07:00March, 2010|Oral Cancer News|

Busting the myth of the cervical cancer vaccine

Source: Temple University Press Editorial by: Gkramer Adina Nack, author of Damaged Goods? Women Living with Incurable Sexually Transmitted Diseases, draws on her expertise as a sexual health researcher to discuss the impact of human papillomavirus (HPV) on men and the need for gender-neutral STD vaccines. When I wrote my book, Damaged Goods? I focused on how living with contagious, stigmatizing, medically incurable (though highly treatable) infections transformed women’s lives – medically, socially and psychologically. I had included a discussion of the Gardasil vaccine, which had received FDA-approval and CDC recommendation for ‘routine’ use in girls and women (ages 9 to 26) back in 2006, and I had articulated some of my concerns about the delayed testing and approval process for ‘male’ Gardasil. A family of viruses, HPV is an ‘equal opportunity infector,’ so why have HPV vaccines not been equally accessible for men as well as women? In a recent interview on Huffington Post, several blog posts of my own, and my new feature article, “Why Men’s Health Is a Feminist Issue” (Ms. Magazine,Winter 2010), I investigate the substantial public health costs that result from HPV vaccines, such as Gardasil, not having been originally developed, tested and approved as gender-neutral vaccines. The narrow and inaccurate marketing of Gardasil as a female-only, “cervical cancer” vaccine has distracted us from public discourse about this family of sexually transmitted viruses that are not only a U.S. epidemic but also a global pandemic. In the U.S., HPV is estimated to affect 75% of adults and certain strains are known [...]

Charlotte Parker2010-03-23T22:33:02-07:00March, 2010|Oral Cancer News|